• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
GAO Yuanyue, LIU Aiyun, SHEN Jiajia, DING Ya. Advances in asialoglycoprotein receptor-mediated liver cancer targeted drug delivery system[J]. Journal of China Pharmaceutical University, 2016, 47(5): 537-542. DOI: 10.11665/j.issn.1000-5048.20160505
Citation: GAO Yuanyue, LIU Aiyun, SHEN Jiajia, DING Ya. Advances in asialoglycoprotein receptor-mediated liver cancer targeted drug delivery system[J]. Journal of China Pharmaceutical University, 2016, 47(5): 537-542. DOI: 10.11665/j.issn.1000-5048.20160505
shu

Advances in asialoglycoprotein receptor-mediated liver cancer targeted drug delivery system

More Information
    Graphical Abstract
    • Abstract
  • Asialoglycoprotein receptor(ASGPR)is a receptor expressed mainly on the surface of liver sinusoidal and basolateral cells. It can exclusively identity, combine and clear desialylated glycoproteins with exposed non-reducing D-galactose(Gal)or nacetylgalactosamine(GalNAc)as end groups. Based on this characteristic, ASGPR-mediated targeted liver cancer therapy has drawn extensive attention. The present review details the latest research progress of this field in three aspects, glycosylated prodrug, small molecular nanocarriers, and glycosylated gene complex therapy system.
    • FullText(HTML)
    • References (30)
  • [1]
    Singh GK,Siahpush M,Altekruse SF.Time trends in liver cancer mortality,incidence,and risk factors by unemployment level and race/ethnicity,United States,1969-2011[J].J Community Health,2013,38(5):926-940.
    [2]
    Stockert RJ.The asialoglycoprotein receptor:relationships between structure,function,and expression[J].Physiol Rev,1995,75(3):591-610.
    [3]
    Ma Y,Chen H,Su S,et al.Galactose as broad ligand for multiple tumor imaging and therapy[J].J Cancer,2015,6(7):658-670.
    [4]
    Lu L, Guo Y, Xu L, et al. Galactosylation of caffeic acid by an engineered β-galactosidase[J]. Drug Discov Ther,2015,9(2):123-128.
    [5]
    Singh Y,Palombo M,Sinko PJ.Recent trends in targeted anticancer prodrug and conjugate design[J].Curr Med Chem,2008,15(18):1802-1826.
    [6]
    Fiume L,Mattioli A,Balboni PG,et al.Enhanced inhibition of virus DNA synthesis in hepatocytes by trifluorothymidine coupled to asialofetuin[J].FEBS Lett,1979,103(1):47-51.
    [7]
    Muro S.Challenges in design and characterization of ligand-targeted drug delivery systems[J].J Control Release,2012,164(2):125-137.
    [8]
    Fiume L,Mattioli A,Busi C,et al.Selective penetration and pharmacological activity of lactosaminated albumin conjugates of adenine arabinoside 5-monophosphate(ara-AMP)in mouse liver[J].Gut,1984,25(12):1392-1398.
    [9]
    Wang J,Wu W,Zhang Y,et al.The combined effects of size and surface chemistry on the accumulation of boronic acid-rich protein nanoparticles in tumors[J].Biomaterials,2014,35(2): 866-878.
    [10]
    Dodeur M,Durand D,Dumont J,et al.Effects of streptozotocin-induced diabetes mellitus on the binding and uptake of asialoorosomucoïd by isolated hepatocytes from rats[J].Eur J Biochem, 1982,123(2):383-387.
    [11]
    Hillaireau H,Couvreur P.Nanocarriers′ entry into the cell:relevance to drug delivery[J].Cell Mol Life Sci,2009,66(17):2873-2896.
    [12]
    Zou Y, Song Y, Yang W, et al. Galactose-installed photo-crosslinked pH-sensitive degradable micelles for active targeting chemotherapy of hepatocellular carcinoma in mice[J].J Control Release,2014,193:154-161.
    [13]
    Zhong Y,Yang W,Sun H,et al.Ligand-directed reduction-sensitive shell-sheddable biodegradable micelles actively deliver doxorubicin into the nuclei of target cancer cells[J]. Biomacromolecules,2013,14(10):3723-3730.
    [14]
    Chen W,Meng F,Cheng R,et al.Biodegradable glycopolymer-b-poly(ε-caprolactone)block copolymer micelles: versatile construction,tailored lactose functionality,and hepatoma-targeted drug delivery[J].J Mater Chem B,2015,3(11):2308-2317.
    [15]
    Schettini DA,Ribeiro RR,Demicheli C,et al.Improved targeting of antimony to the bone marrow of dogs using liposomes of reduced size[J].Int J Pharm,2006,315(1):140-147.
    [16]
    Zhang H,Xiao Y,Cui S,et al.Novel galactosylated poly(ethylene glycol)-cholesterol for liposomes as a drug carrier for hepatocyte-rargeting[J].J Nanosci Nanotechnol,2015,15(6): 4058-4069.
    [17]
    Pathak PO, Nagarsenker MS, Barhate CR, et al. Cholesterol anchored arabinogalactan for asialoglycoprotein receptor targeting:synthesis,characterization,and proof of concept of hepatospecific delivery[J].Carbohyd Res,2015,408:33-43.
    [18]
    Villa R,Cerroni B,Viganò L,et al.Targeted doxorubicin delivery by chitosan-galactosylated modified polymer microbubbles to hepatocarcinoma cells[J].Colloids Surf B Biointerfaces, 2013,110:434-442.
    [19]
    Lundquist JJ,Toone EJ.The cluster glycoside effect[J].Chem Rev,2002,102(2):555-578.
    [20]
    She W,Pan D,Luo K,et al.PEGylated dendrimer-doxorubicin cojugates as pH-sensitive drug delivery systems:synthesis and in vitro characterization[J].J Biomed Nanotechnol,2015,11(6): 964-978.
    [21]
    Duncan B,Kim C,Rotello VM.Gold nanoparticle platforms as drug and biomacromolecule delivery systems[J].J Control Release,2010,148(1):122-127.
    [22]
    Ding Y,Liang JJ,Geng DD,et al.Development of a liver-targeting gold-PEG-galactose nanoparticle platform and a structure-function study[J].Part Part Syst Char,2014,31(3): 347-356.
    [23]
    Zhang Y,Chen T,Yuan P,et al.Encapsulation of honokiol into self-assembled pectin nanoparticles for drug delivery to HepG2 cells[J].Carbohydr Polym,2015,133:31-38.
    [24]
    Ding Y,Bao L,Zhang WJ.Preparation and photocatalytic property of magnetic Fe3O4-TiO2 nanoparticles with a core-shell structure[J].J China Pharm Univ(中国药科大学学报),2010,41(4):312-316.
    [25]
    An J,Zhang X,Guo Q,et al.Glycopolymer modified magnetic mesoporous silica nanoparticles for MR imaging and targeted drug delivery[J].Colloids Surf A Physicochem Eng Asp,2015,482:98-108.
    [26]
    Xiao B,Wang X,Qiu Z,et al.A dual-functionally modified chitosan derivative for efficient liver-targeted gene delivery[J].J Biomed Mater Res A,2013,101(7):1888-1897.
    [27]
    Thapa B, Kumar P, Zeng H, et al. Asialoglycoprotein receptor-mediated gene delivery to hepatocytes using galactosylated polymers[J].Biomacromolecules,2015,16(9):3008-3020.
    [28]
    Devarasu T,Saad R,Ouadi A,et al.Potent calcium phosphate nanoparticle surface coating for in vitro and in vivo siRNA delivery:a step toward multifunctional nanovectors[J].J Mater Chem B, 2013,1(36):4692-4700.
    [29]
    Han L,Tang C,Yin C.Oral delivery of shRNA and siRNA via multifunctional polymeric nanoparticles for synergistic cancer therapy[J].Biomaterials,2014,35(15):4589-4600.
    [30]
    Sajeesh S,Lee TY,Kim JK,et al.Efficient intracellular delivery and multiple-target gene silencing triggered by tripodal RNA based nanoparticles:a promising approach in liver-specific RNAi delivery[J].J Control Release,2014,196:28-36.
    • Related Articles

  • Related Articles

    [1]LI Zhiyan, LI Xianghui, AI Shichao, YIN Yi, LIU Song, GUAN Wenxian. Application of nanomedicines targeting non-glucose nutrients in tumor starvation therapy[J]. Journal of China Pharmaceutical University, 2022, 53(4): 392-399. DOI: 10.11665/j.issn.1000-5048.20220402
    [2]PAN Xiuhua, WU Zhenghong, QI Xiaole. Research status and application progress of CRISPR/Cas9 delivery system[J]. Journal of China Pharmaceutical University, 2020, 51(1): 10-18. DOI: 10.11665/j.issn.1000-5048.20200102
    [3]JI Liyang, HAO Jing, WANG Guocheng, XIE Weijia. Research progress on stimulator of interferon genes agonists for cancer immunotherapy[J]. Journal of China Pharmaceutical University, 2020, 51(1): 1-9. DOI: 10.11665/j.issn.1000-5048.20200101
    [4]SUN Xiaofeng, LIU Tao, LING Yun, CHEN Zhengwei, PAN Zihao, XU Zite, LUO Ling. Advances in research of hyaluronic acid modified nanomicelles for targeting tumor therapy and drug release behavior[J]. Journal of China Pharmaceutical University, 2019, 50(6): 641-647. DOI: 10.11665/j.issn.1000-5048.20190602
    [5]XU Xiangting, WANG Wei. Advances of functionalized carbon nanotubes in diagnosis and treatment of tumor[J]. Journal of China Pharmaceutical University, 2018, 49(2): 165-172. DOI: 10.11665/j.issn.1000-5048.20180205
    [6]CAI Han, LIU Yanhong, YIN Tingjie, ZHOU Jianping, HUO Meirong. Advances in the targeted therapy of tumor-associated fibroblasts[J]. Journal of China Pharmaceutical University, 2018, 49(1): 20-25. DOI: 10.11665/j.issn.1000-5048.20180103
    [7]ZHANG Ran, TIAN Hong, GAO Xiangdong, YAO Wenbing. Application of next generation genome editing technology in gene therapy and biopharmaceuticals[J]. Journal of China Pharmaceutical University, 2014, 45(4): 504-510. DOI: 10.11665/j.issn.1000-5048.20140421
    [8]JIANG Hulin. Biocompatible polymers for gene delivery in cancer gene therapy[J]. Journal of China Pharmaceutical University, 2013, 44(5): 476-481. DOI: 10.11665/j.issn.1000-5048.20130518
    [9]YAO Jing, FAN Ying, ZHOU Jian-ping, LI Fei-yan. Advances on the study of new cationic polymers as gene vectors[J]. Journal of China Pharmaceutical University, 2011, 42(2): 176-181.
    [10]Pharmacokinetics of Magnetic Nanoparticles as Drug Carrier and Their Applications in Cancer Diagnosis and Therapy[J]. Journal of China Pharmaceutical University, 2003, (3): 85-88.

Catalog

    Get Citation
    PDF
    XML
    Article views (1193) PDF downloads (2506) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：290221

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return